Genome sequence of E. coli O104:H4 leads to rapid development of a targeted antimicrobial agent against this emerging pathogen.
Identifieur interne : 000A06 ( Main/Corpus ); précédent : 000A05; suivant : 000A07Genome sequence of E. coli O104:H4 leads to rapid development of a targeted antimicrobial agent against this emerging pathogen.
Auteurs : Dean Scholl ; Dana Gebhart ; Steven R. Williams ; Anna Bates ; Robert MandrellSource :
- PloS one [ 1932-6203 ] ; 2012.
English descriptors
- KwdEn :
- Anti-Infective Agents (pharmacology), Base Sequence (MeSH), Drug Resistance, Bacterial (drug effects), Drug Resistance, Bacterial (genetics), Electrophoresis, Polyacrylamide Gel (MeSH), Escherichia coli (drug effects), Escherichia coli (genetics), Genome, Bacterial (genetics), Lipopolysaccharides (isolation & purification), Mutation (genetics), Silver Staining (MeSH).
- MESH :
- chemical , isolation & purification : Lipopolysaccharides.
- chemical , pharmacology : Anti-Infective Agents.
- drug effects : Drug Resistance, Bacterial, Escherichia coli.
- genetics : Drug Resistance, Bacterial, Escherichia coli, Genome, Bacterial, Mutation.
- Base Sequence, Electrophoresis, Polyacrylamide Gel, Silver Staining.
Abstract
A recent widespread outbreak of Escherichia coli O104:H4 in Germany demonstrates the dynamic nature of emerging and re-emerging food-borne pathogens, particularly STECs and related pathogenic E. coli. Rapid genome sequencing and public availability of these data from the German outbreak strain allowed us to identify an O-antigen-specific bacteriophage tail spike protein encoded in the genome. We synthesized this gene and fused it to the tail fiber gene of an R-type pyocin, a phage tail-like bacteriocin, and expressed the novel bacteriocin such that the tail fiber fusion was incorporated into the bacteriocin structure. The resulting particles have bactericidal activity specifically against E. coli strains that produce the O104 lipopolysaccharide antigen, including the outbreak strain. This O-antigen tailspike-R-type pyocin strategy provides a platform to respond rapidly to emerging pathogens upon the availability of the pathogen's genome sequence.
DOI: 10.1371/journal.pone.0033637
PubMed: 22432037
PubMed Central: PMC3303846
Links to Exploration step
pubmed:22432037Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Genome sequence of E. coli O104:H4 leads to rapid development of a targeted antimicrobial agent against this emerging pathogen.</title><author><name sortKey="Scholl, Dean" sort="Scholl, Dean" uniqKey="Scholl D" first="Dean" last="Scholl">Dean Scholl</name><affiliation><nlm:affiliation>AvidBiotics Corporation, South San Francisco, California, United States of America. dean@avidbiotics.com</nlm:affiliation></affiliation></author><author><name sortKey="Gebhart, Dana" sort="Gebhart, Dana" uniqKey="Gebhart D" first="Dana" last="Gebhart">Dana Gebhart</name></author><author><name sortKey="Williams, Steven R" sort="Williams, Steven R" uniqKey="Williams S" first="Steven R" last="Williams">Steven R. Williams</name></author><author><name sortKey="Bates, Anna" sort="Bates, Anna" uniqKey="Bates A" first="Anna" last="Bates">Anna Bates</name></author><author><name sortKey="Mandrell, Robert" sort="Mandrell, Robert" uniqKey="Mandrell R" first="Robert" last="Mandrell">Robert Mandrell</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22432037</idno><idno type="pmid">22432037</idno><idno type="doi">10.1371/journal.pone.0033637</idno><idno type="pmc">PMC3303846</idno><idno type="wicri:Area/Main/Corpus">000A06</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A06</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Genome sequence of E. coli O104:H4 leads to rapid development of a targeted antimicrobial agent against this emerging pathogen.</title><author><name sortKey="Scholl, Dean" sort="Scholl, Dean" uniqKey="Scholl D" first="Dean" last="Scholl">Dean Scholl</name><affiliation><nlm:affiliation>AvidBiotics Corporation, South San Francisco, California, United States of America. dean@avidbiotics.com</nlm:affiliation></affiliation></author><author><name sortKey="Gebhart, Dana" sort="Gebhart, Dana" uniqKey="Gebhart D" first="Dana" last="Gebhart">Dana Gebhart</name></author><author><name sortKey="Williams, Steven R" sort="Williams, Steven R" uniqKey="Williams S" first="Steven R" last="Williams">Steven R. Williams</name></author><author><name sortKey="Bates, Anna" sort="Bates, Anna" uniqKey="Bates A" first="Anna" last="Bates">Anna Bates</name></author><author><name sortKey="Mandrell, Robert" sort="Mandrell, Robert" uniqKey="Mandrell R" first="Robert" last="Mandrell">Robert Mandrell</name></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Infective Agents (pharmacology)</term><term>Base Sequence (MeSH)</term><term>Drug Resistance, Bacterial (drug effects)</term><term>Drug Resistance, Bacterial (genetics)</term><term>Electrophoresis, Polyacrylamide Gel (MeSH)</term><term>Escherichia coli (drug effects)</term><term>Escherichia coli (genetics)</term><term>Genome, Bacterial (genetics)</term><term>Lipopolysaccharides (isolation & purification)</term><term>Mutation (genetics)</term><term>Silver Staining (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Lipopolysaccharides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Drug Resistance, Bacterial</term><term>Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Drug Resistance, Bacterial</term><term>Escherichia coli</term><term>Genome, Bacterial</term><term>Mutation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Base Sequence</term><term>Electrophoresis, Polyacrylamide Gel</term><term>Silver Staining</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A recent widespread outbreak of Escherichia coli O104:H4 in Germany demonstrates the dynamic nature of emerging and re-emerging food-borne pathogens, particularly STECs and related pathogenic E. coli. Rapid genome sequencing and public availability of these data from the German outbreak strain allowed us to identify an O-antigen-specific bacteriophage tail spike protein encoded in the genome. We synthesized this gene and fused it to the tail fiber gene of an R-type pyocin, a phage tail-like bacteriocin, and expressed the novel bacteriocin such that the tail fiber fusion was incorporated into the bacteriocin structure. The resulting particles have bactericidal activity specifically against E. coli strains that produce the O104 lipopolysaccharide antigen, including the outbreak strain. This O-antigen tailspike-R-type pyocin strategy provides a platform to respond rapidly to emerging pathogens upon the availability of the pathogen's genome sequence.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22432037</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Genome sequence of E. coli O104:H4 leads to rapid development of a targeted antimicrobial agent against this emerging pathogen.</ArticleTitle><Pagination><MedlinePgn>e33637</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0033637</ELocationID><Abstract><AbstractText>A recent widespread outbreak of Escherichia coli O104:H4 in Germany demonstrates the dynamic nature of emerging and re-emerging food-borne pathogens, particularly STECs and related pathogenic E. coli. Rapid genome sequencing and public availability of these data from the German outbreak strain allowed us to identify an O-antigen-specific bacteriophage tail spike protein encoded in the genome. We synthesized this gene and fused it to the tail fiber gene of an R-type pyocin, a phage tail-like bacteriocin, and expressed the novel bacteriocin such that the tail fiber fusion was incorporated into the bacteriocin structure. The resulting particles have bactericidal activity specifically against E. coli strains that produce the O104 lipopolysaccharide antigen, including the outbreak strain. This O-antigen tailspike-R-type pyocin strategy provides a platform to respond rapidly to emerging pathogens upon the availability of the pathogen's genome sequence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scholl</LastName><ForeName>Dean</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>AvidBiotics Corporation, South San Francisco, California, United States of America. dean@avidbiotics.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebhart</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Bates</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mandrell</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AI085318</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R43 AI084295</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R43AI084295</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21AI085318</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024881" MajorTopicYN="N">Drug Resistance, Bacterial</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016680" MajorTopicYN="N">Genome, Bacterial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016622" MajorTopicYN="N">Silver Staining</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>01</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>02</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22432037</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0033637</ArticleId><ArticleId IdType="pii">PONE-D-12-02619</ArticleId><ArticleId IdType="pmc">PMC3303846</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Microbiol. 2001 Mar;39(5):1237-47</Citation><ArticleIdList><ArticleId IdType="pubmed">11251840</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Microbiol. 2011 Dec;193(12):883-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21713444</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochimie. 2002 May-Jun;84(5-6):499-510</Citation><ArticleIdList><ArticleId IdType="pubmed">12423794</ArticleId></ArticleIdList></Reference><Reference><Citation>Appl Microbiol. 1972 Jan;23(1):164-5</Citation><ArticleIdList><ArticleId IdType="pubmed">4621792</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1974 Apr;129(4):470-2</Citation><ArticleIdList><ArticleId IdType="pubmed">4206249</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bacteriol. 1984 Feb;157(2):632-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6420392</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbohydr Res. 1987 Dec 15;170(2):193-206</Citation><ArticleIdList><ArticleId IdType="pubmed">3325166</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Microbiol. 1991 Jan;5(1):71-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2014005</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bacteriol. 1991 May;173(9):2823-32</Citation><ArticleIdList><ArticleId IdType="pubmed">1708379</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbohydr Res. 1992 Dec 15;236:195-208</Citation><ArticleIdList><ArticleId IdType="pubmed">1291048</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1998 Oct 10;352(9135):1207-12</Citation><ArticleIdList><ArticleId IdType="pubmed">9777854</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biochem. 1964 Jan;55:59-64</Citation><ArticleIdList><ArticleId IdType="pubmed">14116621</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 2005 Dec;150(12):2609-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16096708</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 2007 Apr;75(4):1661-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17158899</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2008 May;52(5):1647-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18332164</ArticleId></ArticleIdList></Reference><Reference><Citation>Appl Environ Microbiol. 2008 Jun;74(12):3868-76</Citation><ArticleIdList><ArticleId IdType="pubmed">18441117</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Microbiol. 2008 Jul;69(2):303-16</Citation><ArticleIdList><ArticleId IdType="pubmed">18547389</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Genet. 2009 Jan;5(1):e1000344</Citation><ArticleIdList><ArticleId IdType="pubmed">19165319</ArticleId></ArticleIdList></Reference><Reference><Citation>FEMS Microbiol Lett. 2009 Mar;292(2):182-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19210675</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Jul;53(7):3074-80</Citation><ArticleIdList><ArticleId IdType="pubmed">19349519</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Lab Med. 2010 Mar;30(1):21-45</Citation><ArticleIdList><ArticleId IdType="pubmed">20513540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2010 Oct 23;376(9750):1428-35</Citation><ArticleIdList><ArticleId IdType="pubmed">20971366</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2011 Aug 25;365(8):718-24</Citation><ArticleIdList><ArticleId IdType="pubmed">21793736</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2011 Aug 25;365(8):709-17</Citation><ArticleIdList><ArticleId IdType="pubmed">21793740</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2011 Sep;11(9):671-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21703928</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2011 Oct 20;478(7369):287</Citation><ArticleIdList><ArticleId IdType="pubmed">22012349</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2011 Nov 10;365(19):1771-80</Citation><ArticleIdList><ArticleId IdType="pubmed">21696328</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2011 Nov 10;365(19):1763-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22029753</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2011 Dec;55(12):5469-74</Citation><ArticleIdList><ArticleId IdType="pubmed">21947394</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Microbiol. 2002 Apr;10(4):179-86</Citation><ArticleIdList><ArticleId IdType="pubmed">11912025</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Terre/explor/SilverBacteriV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A06 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000A06 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Terre
|area= SilverBacteriV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:22432037
|texte= Genome sequence of E. coli O104:H4 leads to rapid development of a targeted antimicrobial agent against this emerging pathogen.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:22432037" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SilverBacteriV1
| This area was generated with Dilib version V0.6.38. |  |